We have determined the primary structure of human placental factor XIJ1a, an enzyme [fibrinoligase, transglutaminase, fibrin-stabilizing factor, EC 2.3.2.13 (protein-glutamine:amine r-glutamyltransferase)] that forms intermolecular isopeptide bonds between fibrin molecules as the last step in blood coagulation. Placental factor XIa is an unglycosylated polypeptide chain of 730 amino acid residues (Mr = 83,005) that appears to be identical to the a subunit of the plasma zymogen factor XI. Ca2+-dependent activation of factor XHIa by thrombin removes a blocked amino-terminal peptide and unmasks a reactive thiol group at Cys-314. A second specific cleavage after Lys-513 by thrombin inactivates factor XIIa and produces an amino-terminal 56-kDa fragment and a 24-kDa fragment. The amino acid sequence of factor XIIa is unique and does not exhibit internal homology, but its active center is similar to that of the thiol proteases. The probable Ca2+-binding site of factor XIa has been identified by homology to the high-affmity sites in calmodulins. Knowledge of the primary structure of factor XMa will aid elucidation of the mechanism of its enzymatic action and that of the many tissue transglutaminases ofwhich it is the prototype. This will also facilitate production of factor XIa by recombinant DNA technology for use in treatment of congenital factor XIII deficiencies and in the postoperative healing of wounds.
ase)] is the last enzyme generated in the blood coagulation cascade (1, 2) . It is a transglutaminase or transamidating enzyme that forms intermolecular y-glutamyl-e-lysine crosslinks between fibrin molecules, thereby stabilizing the fibrin clot mechanically and also conferring resistance to proteolysis. FXIIIa has a cysteine thiol active site; however, unlike thiol proteases such as cathepsins B and H that cleave peptide bonds, FXIIIa forms intermolecular isopeptide bridges in fibrin. Other substrates for FXIIIa include coagulation factor V, a2-macroglobulin, platelet myosin, actin, and fibronectin. Thus, in addition to its essential role in blood clotting, FXIIIa may function to stabilize cell surface molecules and membranes. FXIIIa is the prototype of a class of Ca2+-dependent transglutaminases with thiol active centers that are widespread in animal tissues and have been associated with cell proliferation, embryonic development, and growth (3) (4) (5) . However, none except FXIIIa has been puri-, fled and characterized, and until now little has been published about the structure of FXIIIa except the sequence of the amino-terminal activation peptide of the human (6) and bovine (7) plasma FXIIIa. We report here the primary structure of human placental FXIIIa, including the sequence at the active site, and the sites of activation and inactivation by thrombin and the probable Ca2`-binding site.
FXIIIa is formed by a two-step activation of the proenzyme FXIII, which is present in plasma as a tetrameric noncovalent complex (Mr = 340,000) composed of two catalytic a chains (M, = 83,000) and two noncatalytic b chains (Mr = 85,000) with the formula a2b2 (1-3). However, platelet and placental FXIII lack b chains and have the subunit composition a2. The b chain has no role for FXIIIa activity, but it is thought to have a protective function for circulating plasma FXIII. Although composed only of a chains, the platelet and placental enzymes (FXIIIa) are activated by thrombin and Ca2+ in a manner similar to that for the plasma FXIII zymogen (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . Results described here indicate that human FXIIIa molecules derived from plasma, platelets, and placenta are apparently identical in primary structure. Although the terms FXIIIa* and FXIIIa2 are used by various authors to refer to the activated plasma enzyme (2, 3), here we use FXIIIa to refer to the placental a chain subunit on which structural studies were done and no activity measurements made.
By methods of protein chemistry we have determined the complete amino acid sequence of human placental FXIIIa. Using our peptide sequences to design oligonucleotide probes, Grundmann et al. (11) have cloned the placental FXIIIa gene and determined its cDNA sequence. Prior to publication we exchanged data. Except for a few minor differences attributable to genetic polymorphism or to procedural problems, the amino acid sequence determined for the protein and that deduced from the cDNA are identical. On the basis of our studies and earlier data, we propose a molecular model for FXIIIa that shows the sites of activation and inactivation by thrombin and the location of the reactive thiol center and of a putative Ca2+-binding domain. (12) , in which a TSK G4000SW column (7.5 mm i.d. x 60 cm, 8020 Biochemistry: Takahashi et al.
MATERIALS AND METHODS
Methods. Methods used for the determination of the primary structure of proteins in our laboratory have been described (13) (14) (15) (16) (Fig. 1) . The amino end group of placental FXIIIa is blocked; presumably the amino-terminal serine is N-acetylated, as it is in human plasma and platelet FXIIIa (6) and in bovine plasma FXIIIa (7) . The amino acid composition deduced from the protein sequence (Table 1) agrees well with that of Bohn and Schwick (8) . It was surprising that no carbohydrate was detectable despite the presence of the six potential sites for N-glycosylation (see Table 1 ). Glucosamine was not present in any of the peptides isolated. Furthermore, in all peptides containing a potential N-glycosylation site, asparagine was clearly identified by automated sequence analysis, whereas a blank would have been obtained if the asparagine were glycosylated. We identified three free sulfhydryl groups in addition to the thiol at the active site. We found no direct evidence for disulfide bonds. This accords with reports that human plasma FXIIIa has no disulfide bonds (3, 17 end group and by the poor solubility of FXIIIa and the 56-kDa and 24-kDa fragments and their tendency to aggregate. Although the amino terminus of intact FXIIIa is blocked, an amino-terminal tryptic peptide with a free serine end group was obtained in a small amount but sufficient to prove the sequence. However, the last few residues of the FXIIIa sequence (from Arg-727 on) are uncertain because the carboxyl terminus of the protein appears to be heterogeneous. The amino acid sequence of. PXIIIa is unique. Unlike many other plasma proteins (13) (14) (15) (16) 19 ), FXIIIa does not exhibit significant internal homology in sequence that is detectable by the computer programs we used.
Comparison of the Protein Seqdence with the Amino Acid
Sequence Derived from cDNA. The sequence that we determined by amino acid sequence analysis of the FXIIIa protein is identical with that derived from the cDNA sequence (11) except for four positions, all of which are compatible with a single-base change. In addition, there is some heterogeneity at the carboxyl terminus of the protein. We have evidence for polymorphism at positions 77 and 78. There the sequence Arg-Arg is given by us in Fig. 2 and by Grundmann et al. (11) , but we also found Gly-Lys in a chymotryptic peptide. At position 88 we found phenylalanine and not leucine as given by the cDNA sequence; leucine was not present in the tryptic and chymotryptic peptides that included this position. This difference may reflect genetic polymorphism or procedural problems. At position 651 we obtained glutamic acid rather than glutamine given by the cDNA sequence. Our result is based both on sequence analysis and on the specificity of V8 Ser-Phe-Tyr-Val-Gl I le-AspPheSer-Arg-Pr -Tyr-Asp-ProArrArrAsp-Let-Phe-Arg-Val-Gl u-TyVal-Ile-Gly-Arg-Tr-Pro-Gl n-61 u-Asn-Lys-Gly-Thr-Tyr-Ile-Pro-Val-Pro, Ar-G1 Lys-Pe-rg-strGoy-Get-Tr-GA1-Gltr-GPr-A uAla-Ser-G1 -ACa-TrI-A1-Lyspt-Hir-GlyHi s-Va1-Lys-Leu-GlroLe -As ar-P e-Pe-Va -Mea-lRVatr Ser-Asp- AsrSer-His-AsrArg-Tyr-Thr-Iele-Thr-Alra-T-Le-Ser-Ala Ile-Thr-PheTyr-
Thr-Gl y-Va -Pr -Lys-Alua-Gld Phe-Lys-Lys-G otThr -PheAspfVal-Thr -LewGcwPre-LerSer-PherLys-Lys-GlwAia-Vanl-Ler e-Gl atmAa-Glty-Gl s-Tyriet-Gloy-GlckLedLepGl The sequence is shown with all peptides necessary for proofof sequence and is supported by all other peptides for which reliable data were obtained. The amino-terminal serine is blocked and probably is N-acetylated. The peptides were obtained by enzymatic digestion and CNBr cleavage (13) (14) (15) (16) of the intact, reduced, and alkylated FXII1a and of the 5&kDa and 24-kDa fragments. The peptides were purified by an automated HPLC system (18 (6) for the human plasma and platelet enzyme, except that we found 37 residues because of an additional valine in the sequence Val-Val-Pro-Arg at the carboxyl terminus. The activation cleavage site of the human enzyme from all three tissue sources is identical and occurs at an arginylglycine bond. The activated a subunit of plasma and platelet FXIII begins with the sequence Gly-Val-Asx-Leu-Glx-Glx (6). This corresponds to the sequence Gly-Val-Asn-Leu-Gln-Glu-that we found for thrombin-cleaved placental FXIIIa. Thus, FXIIIa enzymes from placenta, plasma, and platelets are identical in their amino-terminal sequence and site ofaction by thrombin. A second specific cleavage by thrombin inactivates human plasma and platelet FXIIIa and produces a 56-kDa fragment that contains the reactive thiol group and also a 24-kDa fragment (10) . We found that thrombin produces 56-kDa and 24-kDa fragments from human placental and plasma FXIIIa and that the cleavage pattern is similar for the enzyme from both sources (Fig. 3) . The active thiol group is in Cys-314 in the placental 56-kDa fragment. Although no structural data are available for the plasma and platelet fragments, their known properties are similar to those obtained by thrombin cleavage of placental FXIIIa at the inactivation site.
The Active Site Peptide. The characteristic property used to identify transglutaminases is the Ca2l-dependent covalent incorporation of amines via a cysteine active center that forms a thioester acyl intermediate (1) (2) (3) (4) (5) . Both in human plasma FXIII (20) and in guinea pig liver transglutaminase (21), the tetrapeptide Gly-Gln-Cys-Trp has been identified as the site containing the active cysteine. This sequence is present at positions 312-315 in placental FXIIIa. When a 20-residue sequence from placental FXIIIa was used as a probe in a computer search of the PIR-NBRF database, the most homologous sequences were those around the active site of a series of thiol proteases (Fig. 4) Conditions include an enzyme-to-substrate ratio of 5 units/1 mg in 50 mM Tris-HCl/0.1 M NaCl, pH 7.5 at room temperature, with the reaction stopped by addition of hirudin (Sigma). Incubation times were 0 min (lanes 1 and 5), 30 sec (lanes 2 and 6), 10 min (lanes 3 and 7) , and 24 hr (lanes 4 and 8) . For preparative purposes, the limited digest of placental FXIIIa was separated by TSK G4000SW column chromatography in the presence of 0.1% NaDodSO4. The 56-kDa and 24-kDa fragments were concentrated and purified on a reversed-phase TSK-gel Phenyl-5PW reversed-phase column with a linear gradient of acetonitrile containing 0.1% trifluoroacetic acid. and actinidin (and also ficin and bromelain, for which only the active site sequences are known). Using a consensus sequence for the active histidine site in thiol proteases, we could not identify a possible active histidine in FXIIIa. This fits with the fact that FXIIIa forms isopeptide bonds and does not cleave a-peptide bonds.
Other Cysteine Residues. By measurement of the incorporation of iodo[14C]acetic acid, Chung et al. (17) concluded that all of the free -SH groups of plasma FXIII are in the a chains and that each a chain has six -SH groups and no disulfide bonds. Others showed that there is a single reactive cysteine per a chain (3, 12, 20 (3, 5, 10, 12) .
Because the b subunits are not required for activation, the Ca2l must bind to the a subunits and expose the active site by inducing conformational change. By a computer analysis of the amino acid sequence of FXIIIa, we have identified three potential Ca2l-binding sites that are located in a putative Ca2l-binding domain that overlaps the thrombin inactivation site (Fig. 1) . The most probable binding site is in the sequence from Gln-468 to Asp-479 (Fig. 5) . When the consensus sequence of the high-affinity Ca2+-binding sites of calmodulin (22) was used to search for homology in the entire sequence of FXIIIa, the segment from Gln-468 to Asp-479 gave the highest score. Also, when 30-residue segments of FXIIIa were used to search the PIR-NBRF database for homology, many Ca2 -binding proteins such as calmodulins and parvalbumins gave a high score for the sequence from Gln-468 to Asp-479. Two other segments of FXIIIa also showed homology, but they gave a lower score and are only illustrated schematically in Fig. 1 .
The EF hand-type of high-affinity Ca2+-binding site is characteristically shown as a loop flanked by two a-helices (22) . According to secondary structure predictions (see below), the tight Ca2l-binding site that we propose for FXIIIa active thiol at Cys-314 and, thus, must be accompanied by a major conformational change. The fact that the Ca2l-binding site is located close to the second site of thrombin cleavage may explain the inactivation incurred in this process. Secondary Structure. No information is available from physicochemical measurements about the secondary structure of FXIIIa, so we used the computer programs PRPLOT and CHOFAS to predict the secondary structure by use ofthe Chou-Fasman parameters (24) . Overall, the distribution predicted for the 730 residues is 36% P3-pleated sheet, 35%
,-turn, and 29% a-helix, or approximately one-third in each category. The activation peptide appears to have a random structure, and the Arg-Gly bond cleaved during thrombin activation is located in a p-turn. Up to the active site thiol (Cys-314), the polypeptide chain is predicted to have a structure composed predominantly of p-sheets separated by p-turns with only two or three strong nuclei for a-helices. The active-site Cys-314 begins a long hydrophobic psheet. The carboxyl-half of the chain seems to have a more organized structure than the first half. The thrombin inactivation site after Lys-513 is flanked by p-turns and is followed by a series of well-defined a-helices, p-sheets, and 8-turns. The carboxyl terminus ends in a series of p-sheets and p-turns.
Properties of the b Chain of FXIII. In the course of purification of the a chain of human plasma FXIII, we also purified the b chain. We confirmed reports (3, 9, 10) that the b chain has an Mr of 85,000 in NaDodSO4/PAGE and is immunologically unrelated to the a chain. The amino terminus is not blocked. The sequence of the first 34 residues is unrelated to that of the a chain and is Glu-Glu-Lys-Pro-XGly-Phe-Pro-His-Val-Glu-Asn-Gly-X-Ile-Ala-Gln-Tyr-XTyr-Thr-Phe-Lys-X-Phe-X-X-Pro-Met-Thr-lle-Gly-Lys-Lys-.
Identity of Placental, Plasma, and Platelet FXMa. All previous evidence indicates that human placental, plasma, and platelet FXIIIa are identical in physical, biological, and immunochemical properties (3, 6, 8) ; our work suggests they are also probably identical in primary structure. We have now shown that placental FXIIIa is not distinguishable from the a chain ofplasma FXIII in the following properties: (0) Mr in NaDodSO4/PAGE, (it) immunodiffusion, (iii) thrombin cleavage pattern and products, and (iv) amino acid sequence at the amino terminus and at the active site. Thus, it is likely that FXIIIa from all three tissue sources has the same primary structure.
Knowledge of the amino acid sequence of FXIIIa should greatly aid elucidation of its mechanism of enzymatic action and has facilitated cloning of the FXIIIa gene (11) . Production of pure enzyme by recombinant DNA techniques would have direct application in replacement therapy for patients with congenital FXIIIa deficiencies (1, 9) and also would provide a source of FXIIIa for treatment of traumatic wounds and in postoperative surgery (9) .
